177lu-psma-617
novartis
[' vision']
#asco22 in the vision trial, the benefit with lupsma was present regardless of prior or concurrent therapy used. #nitinvaishampayan 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E